Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001
about
Assessing Risk in Patients with Stable Coronary Disease: When Should We Intensify Care and Follow-Up? Results from a Meta-Analysis of Observational Studies of the COURAGE and FAME EraSelf-reported drug utilization, health, and lifestyle factors among 70-74 year old community dwelling individuals in Western Norway. The Hordaland Health Study (HUSK)Evaluation of the uses of aspirin, statins and ACEIs/ARBs in a diabetes outpatient population in southern ThailandAntihypertensive and lipid lowering treatment in 70-74 year old individuals--predictors for treatment and blood-pressure control: a population based survey. The Hordaland Health Study (HUSK).Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study.Clinically relevant quality measures for risk factor control in primary care: a retrospective cohort study.Sex differences in the risk of stroke and HbA(1c) among diabetic patientsThe association of angina pectoris with heart disease mortality among men and women by diabetes status: the Rancho Bernardo Study.Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies.Differences in the Cardiometabolic Control in Type 2 Diabetes according to Gender and the Presence of Cardiovascular Disease: Results from the eControl Study.Variations in statin prescribing for primary cardiovascular disease prevention: cross-sectional analysisPatient factors influencing the prescribing of lipid lowering drugs for primary prevention of cardiovascular disease in UK general practice: a national retrospective cohort study.Which population groups should be targeted for cardiovascular prevention? A modelling study based on the Norwegian Hordaland Health Study (HUSK).General practitioners' adherence to guidelines on management of dyslipidaemia: ADDITION-DenmarkDiabetes as a risk factor for acute coronary syndrome in women compared with men: a meta-analysis, including 10 856 279 individuals and 106 703 acute coronary syndrome events.Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education.Patterns and predictors of statin prescription in patients with type 2 diabetesLipid lowering treatment patterns and goal attainment in Nordic patients with hyperlipidemia.Why do sales of lipid-lowering drugs vary between counties in Norway? Evidence from the OPPHED Health Study 2000-2001.Statin prescribing according to gender, age and indication: what about the benefit-risk balance?The impact of gender on the long-term morbidity and mortality of patients with type 2 diabetes receiving structured personal care: a 13 year follow-up study.Cardiometabolic comorbidity in antipsychotic treated patients: need for systematic evaluation and treatment.Women at risk of coronary heart disease experience barriers to diagnosis and treatment: a qualitative interview study.Patient and other factors influencing the prescribing of cardiovascular prevention therapy in the general practice setting with and without nurse assessment.
P2860
Q26745091-A5595F85-59D1-4BBD-997C-51BC45E20BF0Q28217448-3850845E-42D3-45AA-BAAF-7FDA2E86B5E6Q28221323-2FED35D3-FE1E-42EA-8A3C-5DB4D4AEE0A5Q33260919-C3B67B23-6FA8-408D-BD3E-8777BDD290FFQ33308322-D4A6E3B3-9F45-4AFF-9F30-7A77F7768461Q33929231-8FE31A46-20B3-471B-A58E-F0A0468CDF60Q34077852-7523880E-2121-47EA-886E-69CEDED1AD12Q34137134-796F89EB-C180-4579-8567-EB19CD523E95Q34251047-B0F2B715-1A56-466A-886D-37089251A775Q34307460-334758DF-C834-4A7C-9FA3-C058E115F024Q34677382-87EE0703-0DFD-423E-BF8B-C0480FCF3209Q34901608-8ED55ED9-1C17-4B94-B9FD-9ECA23DFD122Q36047855-06BA43E9-5586-45A4-9BBB-951223FE1A38Q36230401-AA1A99FD-18B6-4F8E-8C67-C51515C9DCD7Q36254207-D36E4A8D-5C38-4FAA-8A8F-2DD564963C43Q37173972-891DA115-9246-476F-A9EA-59C1A82B4DA4Q37209404-1CE319BB-21FC-4A05-9468-24C611445DEBQ37210033-9A664340-A2C5-4512-A1DD-13D912206990Q40326093-5AAAE882-EECE-4BB3-9A81-7681D8B62090Q40455288-14164785-4E35-4E6B-80ED-E4F717148CB7Q41096831-5DB03846-6BE9-4638-BC45-0D972A9F708FQ46238277-0EBF49FE-231A-46B3-9EE9-EAAC191C8DB0Q46933058-D992AB4F-83EE-4CA2-B76F-229BC60963F1Q53657751-82FB2B6C-14CC-4A44-85ED-AD4196CCEF9A
P2860
Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001
@ast
Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001
@en
Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001
@nl
type
label
Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001
@ast
Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001
@en
Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001
@nl
prefLabel
Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001
@ast
Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001
@en
Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001
@nl
P2093
P2860
P3181
P1476
Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001
@en
P2093
P2860
P304
P3181
P356
10.1111/J.1365-2796.2004.01315.X
P407
P577
2004-04-01T00:00:00Z